Novogen (NASDAQ:KZIA) Research Coverage Started at Canaccord Genuity Group

Canaccord Genuity Group began coverage on shares of Novogen (NASDAQ:KZIA) in a research report sent to investors on Thursday, MarketBeat reports. The brokerage issued a buy rating and a $29.00 price objective on the stock.

A number of other research analysts also recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. Lake Street Capital started coverage on shares of Novogen in a research note on Thursday, June 11th. They set a “buy” rating and a $32.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and set a $34.00 price target on shares of Novogen in a report on Wednesday, July 15th. Finally, Laidlaw started coverage on shares of Novogen in a research report on Wednesday, April 15th. They issued a “buy” rating and a $25.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Novogen currently has an average rating of “Moderate Buy” and a consensus target price of $26.33.

Novogen Stock Performance

NASDAQ KZIA opened at $13.52 on Thursday. The stock’s 50-day simple moving average is $13.27 and its two-hundred day simple moving average is $10.67. Novogen has a twelve month low of $4.86 and a twelve month high of $17.40.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.